Drug Trial Radar · NCT06823284
To Assess the Bioavailability of TK-254RX in Comparison with Oral Flurbiprofen Tablets and the Adhesion of TK-254RX in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Mar 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Jan 21, 2025
Primary completion
Feb 12, 2025
Study completion Feb 24, 2025
Sponsor
- Lead sponsor
- Teikoku Seiyaku Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- SocraTec R&D GmbH; SocraMetrics GmbH; HWI pharma services GmbH
- First posted
- Feb 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a single-center, open-label, multiple-dose trial performed in a 2-period, 2- sequence-cross-over design in healthy volunteers. The primary purpose of this study is to assess non-superiority of the bioavailability of TK-254RX compared with that of a marketed oral flurbiprofen-containing tablet formulation in healthy volunteers in a 2-period, 2- sequence-cross-over design and evaluate adhesion of TK-254RX. Secondary purpose is to assess safety of TK-254RX and residual amount of the patch.
Conditions
- Healthy
Interventions
Esflurbiprofen Topical SystemDrug
The total of two TK-254RX per day for 5 days (one patch applied to left and right lower leg above ankle)
Flurbiprofen tabletDrug
3 tablets per day for 4 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration versus time curve over 24 hours of S-flurbiprofen for TK-254RX and tablet under steady-state conditionsTime frame: Day 5 to Day 6
- Peak Plasma Concentration of S-flurbiprofen for TK-254RX and tablet under steady-state conditionsTime frame: Day 5 to Day 6
- Characterization of patch adhesionTime frame: Day 1 to Day 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SocraTec R&D GmbH Clinical Pharmacology Unit
Mainzerhofplatz 14, Erfurt, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.